期刊文献+

依达拉奉合成工艺研究

Research on synthesis process of edaravone
下载PDF
导出
摘要 提供了一种依达拉奉重结晶精制的方法。工业级依达拉奉为起始原料,无水乙醇为溶剂,活性炭为脱色剂,经高温溶解,热滤过炭,降温结晶得医药级依达拉奉成品。最佳工艺条件为依达拉奉、无水乙醇、活性炭质量比为1:1.25:0.0625,反应温度为80℃,反应时间为0.5 h,搅拌转速为200 r/min,降温至20℃,离心烘干即得依达拉奉产品。在重结晶过程中,依达拉奉的收率为84%。经高效液相色谱仪检测,依达拉奉产品的纯度为99.91%,单杂为0.04%,总杂为0.09%,符合中国药典2020年版的要求。 A method for recrystallization and refinement of edaravone was provided.Industrial grade edaravone is used as starting material,anhydrous ethanol as solvent,activated carbon as decolorizing agent,pharmaceutical grade edaravone finished product was obtained by high temperature dissolution,heat filtration of carbon,and cooling crystallization.The optimal process conditions were as follows:mass ratio of edaravone,anhydrant ethanol and activated carbon was 1:25:0.0625,reaction temperature was 80℃,reaction time was 0.5 h,stirring speed was 200 r/min,cooling to was 20℃,and edaravone products were obtained by centrifugal drying.During the recrystallization process,the yield of edaravone was 84%.After detection by high performance liquid chromatography,the purity of edaravone product was 99.91%,single impurity was 0.04%,total impurity was 0.09%,which meets the requirements of the Chinese Pharmacopoeia 2020 edition.
作者 马宁宁 刘晓莲 杨藏军 韩啸 魏蒙蒙 康倩 Ma Ningning;Liu Xiaolian;Yang Cangjun;Han Xiao;Wei Mengmeng;Kang Qian(Hebei Jiheng Pharmaceutical Corporation Ltd.,Hengshui 053400,China)
出处 《煤炭与化工》 CAS 2023年第6期123-126,共4页 Coal and Chemical Industry
基金 河北省对氨基苯酚衍生物与叶酸药物技术创新中心(199676234H)。
关键词 依达拉奉 重结晶 精制 降温析晶 高效液相色谱 edaravone recrystallization refining cooling crystallization high performance liquid chromatography
  • 相关文献

参考文献10

二级参考文献66

  • 1顾学兰,丁新生,狄晴,赵忠新,陈家慧,李健华.依达拉奉注射液治疗急性脑梗死的临床疗效评价[J].中国新药与临床杂志,2005,24(2):113-116. 被引量:172
  • 2陶琼华,王绍杰,郝志巧.依达拉奉的合成[J].中国医药工业杂志,2004,35(11):643-644. 被引量:8
  • 3顾学兰.依达拉奉的临床研究及进展[J].世界临床药物,2004,25(11):696-698. 被引量:20
  • 4刘燕华,万泱,许军,何志,黄兰岚.正交设计法选择依达拉奉的合成条件[J].中国药业,2006,15(21):43-44. 被引量:6
  • 5三菱化成工业株式会社.含有3-methyl-1phenyl-2-pyrazolin-5-one的性能稳定的注射剂[P].JP:昭63—132833.1988—6—4.
  • 6Eiichi O, Hideo T, Kyuya K, et al. Clinical efficacy of a free radical scavenger, MCI-186 on acute cerebral infarction[J]. Ther Res, 1998,19(4) :533-551.
  • 7Hiroyoshi N, Toshiaki W, Satoski Y, et al. Prophylactic and therapeutic composition for circulatory disorders and method of treatment [P]. US: 4857542,1989-08-15; JP: 61263917,1986-11-21. (CA 1987, 106: 125901)
  • 8(Bal'yan KV, Shtangeev AL. Condensation of diketene with some aliphatic ketones [J]. Zh Obshch Khim, 1954, 24: 238-241.) CA 1954, 49: 4525d
  • 9(Dykhanov NN. Ethyl and butyl acetoacetates [J]. Med Prom SSSR, 1961, 15(1): 42-45.) CA 1961, 57: 9654d
  • 10Takamatsu Y,Yuki S,Watanabe T.Studies on the concentration of 3-methl-1-1pheny1-2-pyrazolin-5-one (MCI-186) in MCA occlusion and reperfusion model of rats[J].Jpn Pharmacol Ther,1997,25(Suppl):1785-1791.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部